2022
Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness
Lin C, Gou M, Pan S, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Luo X, Li CR, Zhang P, Huang J, Hong L, Tan Y. Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness. Neuroscience Letters 2022, 788: 136826. PMID: 35944595, DOI: 10.1016/j.neulet.2022.136826.Peer-Reviewed Original ResearchConceptsBrain cortical thicknessCognitive impairmentCognitive deficitsGray matter thicknessSchizophrenia (MATRICS) Consensus Cognitive BatteryAttention/vigilanceConsensus Cognitive BatteryCortical thicknessSerum Hcy levelsFirst-episode patientsHealthy controlsHigh homocysteineWorking memoryHcy levelsCognitive batteryNegative Symptom ScaleCognitive functionTreatment researchHigh-resolution magnetic resonance imagingSymptom ScaleSandwich enzyme-linked immunosorbentSchizophreniaHigher cortical thicknessImpairmentEnzyme-linked immunosorbentChildhood trauma and cognitive deficits in patients with schizophrenia: mediation by orbitofrontal cortex H-shaped sulci volume
Wang L, Yin Y, Feng W, Zhou Y, Huang J, Zhang P, Chen S, Fan H, Cui Y, Luo X, Tan S, Wang Z, Tian B, Tian L, Li CR, Tan Y. Childhood trauma and cognitive deficits in patients with schizophrenia: mediation by orbitofrontal cortex H-shaped sulci volume. Journal Of Psychiatry And Neuroscience 2022, 47: e209-e217. PMID: 35654451, PMCID: PMC9177195, DOI: 10.1503/jpn.210178.Peer-Reviewed Original ResearchConceptsFirst-episode schizophreniaCTQ total scoresHealthy controlsCognitive functionChildhood Trauma QuestionnaireTotal scoreCognitive deficitsChildhood trauma experiencesMATRICS Consensus Cognitive BatteryChildhood traumaOrbitofrontal cortexWorse cognitive functionTrauma experiencesHigh-resolution MRIRetrospective designPatientsConsensus Cognitive BatterySchizophreniaTraumaSubscoresSmall sample sizeTrauma QuestionnaireComposite scoreLines of evidenceScores
2021
Effects of microRNA-181b-5p on cognitive deficits in first-episode patients with schizophrenia: Mediated by BCL-2
Gou M, Pan S, Tong J, Zhou Y, Han J, Xie T, Yu T, Feng W, Li Y, Chen S, Cui Y, Tian B, Tan MDS, Wang Z, Luo X, Li CR, Zhang P, Huang J, Hong LE, Tan Y, Tian L. Effects of microRNA-181b-5p on cognitive deficits in first-episode patients with schizophrenia: Mediated by BCL-2. Journal Of Psychiatric Research 2021, 136: 358-365. PMID: 33636692, DOI: 10.1016/j.jpsychires.2021.02.003.Peer-Reviewed Original ResearchConceptsFirst-episode patientsBcl-2 mRNAEnzyme Linked Immunosorbent AssayMATRICS Consensus Cognitive BatteryQuantitative real-time PCRCognitive deficitsCognitive functionGender-matched healthy controlsBcl-2Pathogenesis of schizophreniaPeripheral whole bloodExpression levelsNegative Syndrome ScaleBcl-2 protein expressionLinked Immunosorbent AssayBcl-2 protein levelsPeripheral bloodHealthy controlsBcl-2 mRNA levelsReal-time PCRTarget genes Bcl-2Consensus Cognitive BatterySchizophrenia patientsSyndrome ScaleGene Bcl-2Allostatic Load Effects on Cortical and Cognitive Deficits in Essentially Normotensive, Normoweight Patients with Schizophrenia
Zhou Y, Huang J, Zhang P, Tong J, Fan F, Gou M, Cui Y, Luo X, Tan S, Wang Z, Feng W, Yang F, Tian B, Tian L, Savransky A, Hare S, Ryan MC, Goldwaser E, Chiappelli J, Chen S, Kochunov P, Kvarta M, Tan Y, Hong LE. Allostatic Load Effects on Cortical and Cognitive Deficits in Essentially Normotensive, Normoweight Patients with Schizophrenia. Schizophrenia Bulletin 2021, 47: 1048-1057. PMID: 33501486, PMCID: PMC8266595, DOI: 10.1093/schbul/sbaa196.Peer-Reviewed Original ResearchConceptsHigher allostatic loadCognitive deficitsCortical thicknessCortical thinningAllostatic loadCholesterol levelsSchizophrenia patientsLow high-density lipoprotein cholesterolHypersensitive C-reactive proteinHigh-density lipoprotein cholesterolLower total cholesterol levelsDiastolic blood pressureTotal cholesterol levelsC-reactive proteinWaist-hip ratioLeft superior frontal gyrusHigh cholesterol levelsMean cortical thicknessHigher heart rateSuperior frontal gyrusEarly intervention strategiesGray matter integrityNormoweight patientsLipoprotein cholesterolBlood pressure
2020
Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★
Huang J, Zhu Y, Fan F, Chen S, Hong Y, Cui Y, Luo X, Tan S, Wang Z, Shang L, Yuan Y, Zhang J, Yang F, Li CR, Rowland LM, Kochunov P, Zhang F, Hong LE, Tan Y. Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★. Psychiatry Research Neuroimaging 2020, 297: 111043. PMID: 32062167, PMCID: PMC7490244, DOI: 10.1016/j.pscychresns.2020.111043.Peer-Reviewed Original ResearchTreatment-resistant schizophreniaTreatment-responsive patientsHippocampal volumeHealthy controlsSmaller total hippocampal volumesSmaller hippocampal volumesTotal hippocampal volumeAvailable antipsychotic medicationsSevere cognitive dysfunctionLogistic regression analysisSubgroup of schizophreniaGlobal cognitive deficitsCognitive domain deficitsSpecific deficitsAntipsychotic medicationCognitive dysfunctionTreatment resistanceHigh riskHC groupPatientsMemory deficitsCognitive deficitsCognitive functionSchizophreniaSignificant deficits
2019
Putamen gray matter volumes in neuropsychiatric and neurodegenerative disorders.
Luo X, Mao Q, Shi J, Wang X, Li CR. Putamen gray matter volumes in neuropsychiatric and neurodegenerative disorders. World Journal Of Psychiatry And Mental Health Research 2019, 3 PMID: 31328186, PMCID: PMC6641567.Peer-Reviewed Original ResearchGray matter volumePutamen volumeNeurodegenerative disordersMatter volumePutamen gray matter volumesSpectrum disorderParkinson's spectrum disordersAttention deficit hyperactivity disorderSchizophrenia spectrum disordersDeficit hyperactivity disorderMultiple sclerosisLewy bodiesObsessive-compulsive spectrum disordersMajor depressionTreatment outcomesMotor impairmentDopaminergic processesNeurodegenerative conditionsAmphetamine dependenceBipolar disorderAlzheimer's diseaseCognitive deficitsHuntington's diseaseDiseaseHyperactivity disorderPlasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia
Xie T, Li Q, Luo X, Tian L, Wang Z, Tan S, Chen S, Yang G, An H, Yang F, Tan Y. Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia. Cognitive Neurodynamics 2019, 13: 357-365. PMID: 31354881, PMCID: PMC6624222, DOI: 10.1007/s11571-019-09530-3.Peer-Reviewed Original ResearchAttention/vigilanceSpeed of processingTotal antioxidant statusFirst-episode drug-naïve patientsDrug-naïve patientsCognitive impairmentCognitive deficitsSchizophrenia (MATRICS) Consensus Cognitive BatteryMCCB total scoreConsensus Cognitive BatteryHealthy controlsAntioxidant statusPlasma total antioxidant statusSex-matched healthy controlsOxidative stressPlasma TAS levelsPathophysiology of schizophreniaCognitive batteryStroop testNegative Syndrome ScaleReactive oxygen species-induced oxidative damageTreatment researchPsychopathological symptomsFEDN patientsHealthy subjects
2013
Cognitive Function, Plasma MnSOD Activity, and MnSOD Ala-9Val Polymorphism in Patients With Schizophrenia and Normal Controls
Zhang XY, Chen D, Xiu MH, Yang FD, Tan Y, Luo X, Zuo L, Kosten TA, Kosten TR. Cognitive Function, Plasma MnSOD Activity, and MnSOD Ala-9Val Polymorphism in Patients With Schizophrenia and Normal Controls. Schizophrenia Bulletin 2013, 40: 592-601. PMID: 23588476, PMCID: PMC3984504, DOI: 10.1093/schbul/sbt045.Peer-Reviewed Original ResearchConceptsAla-9Val polymorphismNormal controlsCognitive impairmentMnSOD activityAla allele carriersChronic schizophrenic patientsMitochondrial enzyme manganese superoxide dismutaseNegative Syndrome ScaleEnzyme manganese superoxide dismutaseHealthy controlsManganese superoxide dismutaseAllele carriersExcessive reactive oxygen speciesSchizophrenic patientsSchizophrenic inpatientsSyndrome ScaleCognitive deficitsNeuropsychological StatusCognitive functionPatients' psychopathologyRepeatable BatteryPatientsSchizophreniaTotal scoreReactive oxygen species
2012
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls
Zhang XY, Chen DC, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, Kosten TA, Kosten TR. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Human Genetics 2012, 131: 1187-1195. PMID: 22362486, PMCID: PMC3671849, DOI: 10.1007/s00439-012-1150-x.Peer-Reviewed Original ResearchConceptsBDNF Val66Met polymorphismBDNF levelsRBANS total scoreHealthy controlsSchizophrenic patientsVal66Met polymorphismHippocampal-dependent cognitive functionsCognitive deficitsBrain-derived neurotrophic factor (BDNF) geneTotal scoreBDNF serum levelsBDNF Val66Met gene polymorphismPeripheral BDNF levelsSerum BDNF levelsMet variantNeurotrophic factor geneNegative Syndrome ScaleSerum BDNFSerum levelsPatient groupNormal controlsSchizophrenic inpatientsGene polymorphismsSyndrome ScaleCognitive impairment